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Heteroduplex polymerase chain reaction for antigen receptor rearrange-
ments (hPARR) was developed to monitor minimal residual disease (MRD) in 
canine B- and T-cell lymphomas treated with the modified L-COP or L-CHOP 
protocol. Thirty-five dogs were recruited in this study and their neoplastic line-
ages were determined by immunophenotyping with Pax5 and CD3. Peripheral 
blood leukocytes were collected prior to and during chemotherapy in weeks 4, 9 
and 13 to detect MRD by hPARR. Twenty-eight dogs (80%) had B-cell lympho-
ma while seven dogs (20%) had T-cell lymphoma. A monoclonal band was de-
tected in 11 cases that showed complete or partial remission before tumour re-
lapse and no response to the current treatment without statistical difference in 
clinical outcomes; however, the treatment response had an association with the 
MRD result (P < 0.05). Modified L-CHOP prolonged median progression-free 
survival as compared to modified L-COP (215 days vs. 93 days; P < 0.05). Sub-
stage b had shorter progression-free survival than substage a (90 days vs. 215 
days; P < 0.05). Clinical stage III affected median overall survival time when 
compared to clinical stages IV and V (432, 173 and 118 days, respectively; P < 
0.05). hPARR could be used for screening refractory lymphoma together with 
lymph node measurement in routine clinical cases.  
Key words: Chemotherapy, dog, lymphoma, minimal residual disease, 
PARR  
Minimal residual disease (MRD) is a remnant of neoplastic cell that sur-
vives during or after chemotherapeutic treatment. It can be an indicator of tu-
mour relapse and treatment outcome. Because of a low level of malignant cells 
during clinical remission, they should be monitored by advanced sensitive mo-
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lecular methods, such as PCR, real-time PCR or flow cytometry (Calzolari et al., 
2006; Yamazaki et al., 2008; Gentilini et al., 2013; Aresu et al., 2014). If the 
quantity of MRD in patients was increased during or after treatment, this indicat-
ed poor prognosis and inadequate treatment efficacy in human and canine lym-
phomas (Yashima et al., 2003; Pott et al., 2006; Sato et al., 2013). 
Polymerase chain reaction for antigen receptor rearrangements (PARR) is 
a molecular technique that detects alleles of immunoglobulin heavy chain (IgH) 
and T-cell receptor gamma (TCRγ) genes, the antigen-binding receptors of B and 
T lymphocytes, respectively. This technique showed a high sensitivity for detect-
ing clonal B- or T-cell populations from various types of samples in dogs (Bur-
nett et al., 2003). Because neoplastic lymphocytes could circulate in blood, pe-
ripheral blood is a good sample source for MRD screening (Keller et al., 2004; 
Lana et al., 2006; Thilakaratne et al., 2010). Aresu et al. (2014) compared the 
suitability of the flow cytometry and PARR methods to assess MRD in peripher-
al blood, lymph node (LN), and bone marrow samples in canine high-grade B-
cell lymphoma. They found that PARR had higher sensitivity than flow cytome-
try from peripheral blood. Moreover, the MRD-positive cases screened by PARR 
showed a correlation with the time of relapse. In addition, dogs in which MRD 
was detected after complete remission had a shorter survival time than other dogs 
that were free of MRD (Manachai et al., 2012). Therefore, monitoring MRD 
might be a useful method for detecting refractory canine lymphoma. 
Heteroduplex analysis with PARR (hPARR) was recommended for the di-
agnosis of canine lymphoma because it decreased the chance of misdiagnosis due 
to pseudoclonality (Takanosu et al., 2010). After denaturation and slow re-
annealing, it helped the formation of homoduplex molecules with identical size 
and sequence, and rendered defective the re-annealing of heteroduplex molecules 
with identical size and different sequence. Homogenous PCR products then mi-
grated in expected size and showed the monoclonal band in high-resolution gel, 
while heterogeneous products migrated slowly, leading to a diffuse smear pat-
tern. This increased the specificity of interpretation of PCR amplicons and vali-
dation of the clonal results.  
The recommended chemotherapy for canine lymphomas is a L-CHOP pro-
tocol (L-asparaginase, vincristine, cyclophosphamide, doxorubicin, and predniso-
lone) (Garrett et al., 2002). However, a high-dose COP treatment (vincristine, 
cyclophosphamide, and prednisolone) might be one option because it has a lower 
cost (Dobson et al., 2001). Multicentric lymphoma treated with a COP combina-
tion with L-asparaginase (L-COP) or without L-asparaginase showed a complete 
remission rate of 70–80% and had median survival times of 6–7 months (Dobson 
et al., 2001; Jeffreys et al., 2005). However, this treatment has a longer mainte-
nance phase, and shorter progression-free survival (PFS) and overall survival 
time (OST). On the other hand, the maintenance-free L-CHOP treatment has an 
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overall response rate of 90–100% and a prolonged OST of 12 months (Garrett et 
al., 2002; Burton et al., 2013; Curran and Thamm, 2016). 
Although canine lymphoma is responsive to chemotherapy, it could be re-
sistant to antineoplastic drugs due to multidrug-resistance genes (Zandvliet et al., 
2015). LN size evaluation used concurrently with an adjunctive molecular tool 
might provide a tumour burden in non-target lesions other than peripheral lymph 
nodes. The purposes of this study were to monitor MRD in canine B- and T-cell 
lymphomas treated with the modified L-COP (mL-COP) or modified L-CHOP 
(mL-CHOP) protocols by hPARR, and to evaluate the efficacy of treatment. The 
clinical outcomes were correlated with the chemotherapeutic protocols, immuno-
phenotype, clinical stage, substage and MRD results. 
 
 
Materials and methods 
Animals and sample collections 
Thirty-five dogs had been sent to the Oncology Clinic, Small Animal 
Teaching Hospital, Chulalongkorn University in 2013 through 2015 (IACUC 
Number 13310074). They were clinically diagnosed as having multicentric lym-
phoma by cytopathology and/or histopathology according to the WHO criteria. 
All dogs were checked for complete blood count (CBC), liver enzymes (alanine 
aminotransferase, ALT and alkaline phosphatase, ALP), and kidney function 
[blood urea nitrogen (BUN), creatinine, total protein, albumin and globulin]. The 
dogs were examined for blood parasites using thin blood smears and by testing 
the presence of serum antigen of heartworm (Dirofilaria immitis), serum anti-
body against Ehrlichia canis and Anaplasma platys using the SNAP 4Dx Plus 
Test kit (IDEXX, USA). Clinical staging was done on the basis of CBC, thoracic 
and abdominal radiographs, abdominal ultrasound for detecting liver and spleen 
metastasis, and buffy-coated smears for leukaemia assessment. After immuno-
phenotyping, the dogs received the mL-COP or mL-CHOP protocol (Table 1) 
depending on the owner’s decision and the dogs’ cardiac condition. Peripheral 
blood was collected into an EDTA tube in week 0 and during the treatment in 
weeks 4, 9 and 13. Dogs treated with mL-CHOP received a 25-week protocol 
while those treated with mL-COP received a 1-year protocol. After achieving a 
complete remission, the animals were followed up monthly or bimonthly. Physi-
cal examination was performed and CBC as well as hepatic and renal chemistry 
profiles were checked before giving antineoplastic drugs. If patients had abnor-
mal blood results, such as leukopenia, anaemia, increased hepatic or renal values, 
the chemotherapy was postponed until the adverse events were normalised, and 
until that time they received only supportive treatment. 
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Cytopathology/histopathology 
Cytological specimens were collected by fine needle aspiration from en-
larged superficial LNs in those cases that were unsuitable for general anaesthesia 
and biopsy procedures. Four cytological smear slides were prepared for cyto-
pathological classification based on Updated Kiel (Sapierzynski et al., 2010), 
stained by Giemsa, and for immunocytochemistry, immunostained by Pax5 and 
CD3. For the histopathological study, a punch biopsy of 6 mm diameter was ap-
plied to collect samples from enlarged superficial nodes, and the biopsy sample 
was kept in 10% (w/v) neutral buffered formalin. Routine histological processing 
and paraffin wax embedding were performed. Four- to 6-µm-thick sections were 
stained with haematoxylin and eosin (HE) for histopathological classification 
based on the WHO criteria (Valli et al., 2011), and immunostained with Pax5 
and CD3 for immunophenotyping. 
Immunocytochemistry (ICC) 
After fixing the slides with cold acetone for 10 min, they were kept at  
–20 °C until used. In brief, cells on the glass slide were blocked for endogenous 
peroxidase and protein background by 3% (v/v) H2O2 and 1% (w/v) bovine se-
rum albumin (Merck Millipore, USA) in 0.25% phosphate-buffered saline–
Triton X-100 (PBST), followed by incubation with the monoclonal mouse anti-
human Pax5 antibody (1EW; Leica, USA) at a dilution of 1:50 at 4 °C for 12–
14 h. For T-cell detection, cells were treated as B cells above except for using the 
ready-to-use monoclonal mouse anti-human CD3 antibody (LN10; Leica, USA). 
In both cases the signal of the bound antibody was amplified by Novolink poly-
mer (Leica, USA) for 15 min and colour was developed with by 3,3’-
diaminobenzidine (DAB; Leica). Slides were counterstained with Mayer’s hae-
matoxylin for 1 min. Cytological smears from normal canine LN were used as 
negative control. Pax5 showed a nuclear staining in B cells while CD3 showed 
immunoreactivity in the cytoplasm of T cells. B-cell or T-cell lymphomas were 
identified if at least 60% of the cells revealed expression of Pax5 or CD3, respec-
tively (Sirivisoot et al., 2017). 
Immunohistochemistry (IHC) 
In the case of Pax5, antigens were revived by treatment of the slides in 
Tris/EDTA (pH 9.0) in an autoclave oven (121 °C) for 5 min, while for CD3 the 
antigen was retrieved by heating the slides with 10 mM citrated buffer (pH 6.0) 
in a microwave for 6 min twice. Subsequently, the slides were blocked, incubat-
ed with the relevant monoclonal mouse anti-human antibody, and processed as 
described for ICC above. A normal canine lymph node obtained from necropsy 
was used as a staining control. Interpretations of positive B-cell or T-cell lym-
 MINIMAL RESIDUAL DISEASE IN CANINE LYMPHOMAS 71 
Acta Veterinaria Hungarica 66, 2018 
phomas were achieved when at least 60% of the neoplastic cells stained positive 
with Pax5 and CD3, respectively (Sirivisoot et al., 2017). 
MRD by hPARR 
The EDTA-anticoagulated blood was centrifuged at 5,000 rpm for 5 min 
and the peripheral blood leucocytes were separated and kept at –20 °C for DNA 
extraction. Genomic DNA was extracted using a mammalian genomic DNA min-
iprep kit (Sigma-Aldrich, USA) and the obtained DNA concentration was meas-
ured by NanoDrop Lite spectrophotometer (Thermo Fisher Scientific, USA). 
Samples were then analysed for IgH and TCRγ genes by hPARR (Takanosu et 
al., 2010) using the four primer sets in Table 2: the Cμ gene as a control for DNA 
amplification (Burnett et al., 2003), the IgH gene of B lymphocytes (Tamura et 
al., 2006) and two TCRγ gene primer pairs for T lymphocytes (Yagihara et al., 
2007). The DNA and primer concentrations were 50–200 ng and 200–300 nM, 
respectively. The PCR was thermocycled with 35 cycles of 94 °C for 45 sec, 
60 °C for 30 sec, and 72 °C for 30 sec. After conventional PARR, each PCR 
product was divided into two aliquots and one was run for heteroduplex analysis 
by incubation at 95 °C for 5 min and re-annealing at 4 °C for 30 min. Afterwards 
the PCR products were resolved by 2% (w/v) agarose gel electrophoresis and 
visualised with 10% (w/v) ethidium bromide staining by AlphamanagerTM (Alpha 
Innotech, USA). DNase-/RNase-free distilled water was used in place of the 
template as a negative control. ExcelBand 100 bp + 3K DNA ladder (Smobio 
Technology, Taiwan) was used for sample size identification. A monoclonal or 
biclonal band of each gene indicated hPARR positivity, whilst the presence of a 
polyclonal band or no band was regarded as hPARR negative. Biopsy samples 
diagnosed as B- and T-cell lymphomas were used as B- and T-cell positive con-
trols. 
Table 2 
Primer sets used in the hPARR method 
Product Primer names Primer sequence (5'-3') Product size 
Cμ Sigmf1 TTC CCC CTC ATC ACC TGT GA 130 bp 
 Srμ3 GGT TGT TGA TTG CAC TGA GG  
IgH V region ACA CGG CC(A/C/G) TGT ATT ACT GT 80–150 bp 
 J region TGA GGA GAC GGT GAC C  
TCRγ Vγa CGT GTA CTA CTG CGC TGC CTG G 55–90 bp 
 Vγb GGC TGT ATT ACT GTG CCT GCT GG  
 Jγba TGT GCC AGG ACC AAG CAC TTT GTT  
aPrimer Jγb was used with either Vγa or Vγb 
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Follow-up of cases 
Peripheral LN measurements (target lesions: submandibular, prescapular, 
superficial inguinal and popliteal LNs) using callipers were recorded to assess 
treatment efficacy: complete response (CR; disappearance of all target lesions), 
partial response (PR; at least 30% decrease in the sum longest diameter of target 
lesions), stable disease (SD; target lesions showing neither sufficient decrease for 
PR nor sufficient increase for PD), and finally progressive disease (PD; at least 
20% increase in the sum longest diameter of target lesions) (Vail et al., 2010). If 
dogs showed PD and/or hPARR positivity during the treatment in weeks 4, 9, 
and 13 (refractory lymphoma), they received a rescue drug, such as lomustine or 
L-asparaginase with vincristine. Dogs with a complete treatment were followed 
up every one or two months. Each case was noted for PFS and OST. 
Statistical analysis 
PFS and OST were compared by Kaplan-Meier survival analysis between 
B- and T-cell originated lymphomas that were treated with the mL-COP and mL-
CHOP protocols. Dogs, which were still alive at the time of the analysis or had 
been lost to follow up, were censored for the survival analysis. The correlation of 
immunophenotype, treatment, clinical stage, substage, hPARR result and L-
asparaginase treatment with clinical outcomes was analysed by Cox regression. 
The association of clinical response with the MRD result was assessed by Pear-
son’s chi-square test. The SPSS 22 Statistics for Windows software (IBM, USA) 
was used for all analyses, and significance was accepted at the P < 0.05 level. 
 
 
Results 
Signalment 
The signalment data are shown in Table 3. Pure breeds were mainly Golden/ 
Labrador retriever (eight dogs) and Shih Tzu (eight dogs). At the first presenta-
tion, thrombocytopenia (platelet count less than 160,000/µl) was reported in six 
dogs. One dog had anaemia (RBC count less than 5.2 × 106 cells/µl and a haema-
tocrit volume less than 30%). Six dogs had elevated ALT/ALP (values more than 
200 IU/L). One dog had elevated creatinine and BUN (values of more than 1.4 
and 27 mg%, respectively). Three patients were infected with Ehrlichia canis: 
one dog showed elevated serum levels of antibodies to E. canis by the SNAP 
4Dx Plus Test (dog no. 8), and two dogs were found positive by blood smear 
(dogs no. 3 and 11).  
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Table 3 
The signalment of 35 canine lymphomas 
Gender  
Male 21 
Female 14 
Age (years) 3–13 (median 8.5)
Breed  
Pure 30 
Mixed 5 
Clinical stage  
III 19 
IV 12 
V 4 
Substage  
a 24 
b 11 
 
Cytopathology, histopathology and immunophenotype 
Four dogs were diagnosed as having multicentric lymphoma based on 
their cytology due to their condition being unsuitable (too weak) for general an-
aesthesia. Their cytological assessments by the updated Kiel criteria were one 
small lymphocytic lymphoma, one centroblastic monomorphic lymphoma and 
two centroblastic polymorphic lymphomas. The other 31 dogs were histopatho-
logically classified by examination of the affected LN section using the WHO 
scheme based on architecture and immunophenotype, as shown in Table 4. In 
this study, B-cell lymphomas accounted for 80% (28/35) of the dogs and were 
categorised as 8.6% (3/35) low grade and 71.4% (25/35) high grade, while T-cell 
lymphomas accounted for 20% (7/35) of the dogs and were 14.3% (5/35) low 
grade and 5.7% (2/35) high grade. The most common lymphoma subtypes in 
dogs were centroblastic diffuse large B-cell lymphoma (DLBCL CB; Fig. 1A) 
and immunoblastic DLBCL (DLBCL IB). The ICC and IHC results of the B-cell 
lymphomas showed Pax5+/CD3– (Fig. 1B, C), and T-cell lymphomas were Pax5–/ 
CD3+ (Fig. 2B, C). However, one case of T-cell rich large B-cell lymphoma (T-
cell rich LBCL) showed CD3+ T cells around large Pax5+ B cells. 
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Fig. 1. Diffuse large B-cell lymphoma, high-grade centroblastic type treated with modified mL-
CHOP. (A) Histopathology showed starry-sky appearance with evidence of tangible-body macro-
phages. (B) IHC revealed CD3–. (C) Pax5+ immunostained in the nuclei of B cells. Bar = 25 µm. 
(D) The hPARR analysis showed monoclonal IgH genes from white blood cell samples in week 0, 
and in weeks 4 to 13 a diffuse pattern in both IgH and TCRγ genes was evident.  
L = ExcelBand 100 bp ladder; 1 = Cµ gene (130 bp); 2, 5, 8, 11, 14, 17, 20, 23 = IgH genes (120 bp); 
3, 6, 9, 12, 15, 18, 21, 24 = TCRγ-1 genes (90 bp); 4, 7, 10, 13, 16, 19, 22, 25 = TCRγ-2 gene  
(200 bp); 5–7, 11–13, 17–19, 23–25 = heteroduplex analysis; 26 = B-cell lymphoma;  
27 = T-cell lymphoma; 28 = negative control 
 
MRD by hPARR 
By hPARR analysis of the 28 B-cell lymphomas, 16 cases presented a 
clonal band of the IgH gene, eight cases showed TCRγ genes (dogs no. 1, 2, 10, 
13, 16, 18, 26, and 27), and four cases (dogs no. 3, 23, 25, and 28) showed dual 
gene rearrangements. In contrast, 6/7 cases of T-cell lymphomas showed a clonal 
band of the TCRγ gene and one (dog no. 31) showed both IgH and TCRγ genes 
(Table 5). Sensitivity and specificity of the IgH primer sets were 57.1% and 
100%, respectively, while the TCRγ primer sets had 85.7% sensitivity and 66.7% 
specificity. The percentage agreement between the hPARR and the immunophe-
notyping method was 62.9%. 
The mL-COP group consisted of 14 B-cell lymphomas and three T-cell 
lymphomas, while the mL-CHOP group comprised 14 B-cell lymphomas and 
four T-cell lymphomas. In the first group, B-cell lymphomas treated with the 
mL-COP protocol, dog no. 2 showed no response to the treatment and presented 
hPARR positive in week 9 before PD. Dogs no. 4 and 14 with CR showed 
 L 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 
 week 0 week 4 week 9 week 13 
100 bp
D 
A B C
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hPARR positivity during the treatment in week 9 or 13 prior to refractory dis-
ease. Dog no. 13 with PR was hPARR positive throughout the treatment before 
death due to PD. Treatment efficacy of mL-COP showed good response in other 
cases with CR and no molecular response. 
 
 
Fig. 2. T-small lymphocytic lymphoma treated with mL-COP. (A) Histopathology presented small 
neoplastic T cells with cleaved, basophilic nuclei and scant cytoplasm. (B) CD3+ in the cytoplas-
mic membrane of T cells. (C) Pax5–. Bar = 25 µm. (D) The hPARR analysis showed a monoclonal 
TCRγ genes from the white blood cell samples in weeks 0 to 13. L = ExcelBand 100 bp ladder;  
1 = Cµ gene (130 bp); 2, 5, 8, 11, 14, 17, 20, 23 = IgH genes (120 bp); 3, 6, 9, 12, 15, 18, 21, 24 = 
TCRγ-1 genes (90 bp); 4, 7, 10, 13, 16, 19, 22, 25 = TCRγ-2 gene (200 bp); 5–7, 11–13, 17–19, 
23–25 = heteroduplex analysis; 26 = B-cell lymphoma; 27 = T-cell lymphoma;  
28 = negative control 
 
The second group, B-cell lymphoma treated with the mL-CHOP protocol, 
had only three dogs found hPARR positive whilst receiving the antineoplastic 
drugs. Dog no. 15 with PR and dog no. 17 with CR had PD and needed a change 
to a rescue protocol with L-asparaginase and vincristine. However, dog no. 19 
with hPARR positivity subsequently had a prolonged OST before death of an 
unknown cause. The other dogs responded well to the mL-CHOP treatment with 
no detectable molecular response (Fig. 1D).  
In the third group, T-cell lymphomas treated with the mL-COP protocol, 
dog no. 31 failed to achieve clinical response, showed hPARR positivity before 
PD and had to be given the rescue drugs. Dogs no. 29 and 30 with CR presented 
hPARR positive during the treatment, even though they had long PFS or OST 
(Fig. 2D) similarly to the last group, dog no. 32.  
 L 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 
 week 0 week 4 week 9 week 13 
100 bp
D 
A B C
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Table 5 
The MRD results by hPARR from four treatment groups with PFS and OST 
Group Stage Re- sponse 
Pre-
treatment
Post-treatment PFS 
(days) 
OST 
(days) Week 4 Week 9 Week 13
B-cell lymphoma         
Modified COP         
01. B-SLL III CR TCRγ + – – 78 126 
02. B-SLL IV No TCRγ – + R 70 227 
03. T-cell rich LBCL IV CR Dual – – – – 604a 
04. DLBCL IB IV CR IgH – – + 103 239 
05. DLBCL IB III CR IgH – – – 236 371 
06. DLBCL CB III CR IgH – – – – 144 
07. DLBCL CB III PR IgH – – – 24 123 
08. DLBCL CB III CR IgH – – – – 84 
09. DLBCL IB III CR IgH – – – 327 548b 
10. DLBCL CB IV CR TCRγ – – – 89 91 
11. DLBCL IB III CR IgH – – – 90 265 
12. DLBCL CB III CR IgH – – – – 218 
13. DLBCL CB V PR TCRγ + + + 75 89 
14. DLBCL CB III CR IgH – + + 69 93 
Modified CHOP         
15. DLBCL IB IV PR IgH – + + 34 116 
16. DLBCL IB III CR TCRγ – – – – 826a 
17. DLBCL CB IV CR IgH – – + 155 247 
18. DLBCL CB IV CR TCRγ – – – 201 247 
19. DLBCL CB III CR IgH + + + – 338b 
20. DLBCL CB V CR IgH – – – 224 286 
21. DLBCL IB V CR IgH + – – 143 245 
22. DLBCL CB III CR IgH – – – 215 238 
23. DLBCL CB III CR Dual + + – 389 585 
24. DLBCL CB III CR IgH – – – 169 432 
25. DLBCL IB IV CR Dual – – – – 161 
26. DLBCL IB IV CR TCRγ – – – 130 159 
27. DLBCL IB III CR TCRγ – – – 420 597a 
28. DLBCL CB III CR Dual – – – 341 486 
T-cell lymphoma         
Modified COP         
29. T-SLL III CR TCRγ + + + 450 862a 
30. T-SLL V CR TCRγ + + + – 118 
31. T-ALCL IV No Dual + R n/a 35 171 
Modified CHOP         
32. T-SLL III CR TCRγ + + + – 527a 
33. CTCL III CR TCRγ + + – – 569a 
34. PTCL IV CR TCRγ – – – 227 272 
35. PTCL IV CR TCRγ – – – 103 173 
CR = complete remission; PR = partial remission; PFS = progression-free survival; OST = overall sur-
vival time; R = relapse; B- or T-SLL = B- or T-small lymphocytic lymphoma; T-cell rich LBCL = T-cell 
rich large B-cell lymphoma; DLBCL IB = diffuse large B-cell lymphoma immunoblastic; DLBCL CB = 
diffuse large B-cell lymphoma centroblastic; T-ALCL = anaplastic large T-cell lymphoma; CTCL = cu-
taneous T-cell lymphoma; PTCL = peripheral T-cell lymphoma; astill alive; blost to follow-up 
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Treatment response and survival time 
The overall response rate to mL-COP treatment was 88%: 13 dogs had CR 
and two dogs had PR. Two of the 17 dogs had no response. Conversely, the 
overall response rate to the mL-CHOP treatment was 100%: 17 dogs had CR and 
one dog had PR. Two dogs that failed to achieve a CR (dogs no. 2 and 31) had a 
PFS of 70 and 35 days, respectively, with MRD positivity. Three dogs that had a 
PR (dogs no. 7, 13 and 15) had a PFS of 24, 75 and 34 days, respectively, and 
presented hPARR positive before refractory disease. Six dogs were still alive 
during the time of analysis and two dogs had been lost for contact (Table 5). The 
treatment response was correlated with the MRD result; cases with CR to the 
treatment tended to be MRD negative (P = 0.03, Chi-square test). However, sev-
en dogs with CR showed MRD positivity before current treatment failure. 
Table 6 
Variables by univariable analysis as prognosis for PFS and OST in 35 dogs 
Parameter Median PFS (days) P value 
Median OST 
(days) P value 
Immunophenotype     
B-cell (28) 155 0.213 239 0.303 
T-cell (7) 227  272  
Substage     
A (24) 215 0.002 247 0.068 
B (11) 90  173  
Clinical stage     
III (19) 236 0.060 432 0.040 
IV (12) 103  173  
V (4) 118  118  
Minimal residual disease     
Present (11) 103 0.518 227 0.618 
Absent (24) 201  247  
L-asparaginase     
With L-asparaginase (21) 155 0.574 245 0.955 
Without L-asparaginase (14) 169  238  
Treatment     
mL-COP (17) 93 0.034 171 0.090 
mL-CHOP (18) 215  272  
 
 
The B-cell lymphoma dogs treated with the mL-COP protocol had a medi-
an PFS of 90 days (95% CI of 82.7 and 97.3 days) and a median OST of 114 
days (95% CI of 0 and 312.7 days), whereas those treated with the mL-CHOP 
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had a median PFS of 201 days (95% CI of 116.7 and 285.3 days) and a median 
OST of 247 days (95% CI of 196.9 and 297.1 days). The T-cell lymphoma dogs 
treated with the mL-COP had a median PFS of 118 days (95% CI of 0 and 250.8 
days) and a median OST of 171 days (95% CI of 86.2 and 255.8 days), while 
those treated with mL-CHOP had a median PFS of 227 days and a median OST 
272 days. Both B-cell and T-cell lymphomas treated with the CHOP protocol 
had longer median PFS (P = 0.04; Log-Rank test) and OST (P = 0.08; Log-Rank 
test) than those receiving the COP-based protocol. By immunophenotyping, B-
cell lymphomas had a median PFS of 155 days (95% CI of 121.3 and 188.7 days) 
and a median OST of 239 days (95% CI of 218.3 and 259.7 days), while T-cell 
lymphomas had a median PFS of 227 days (95% CI of 0 and 506.7 days) and a 
median OST of 272 days (95% CI of 17.9 and 526.1 days) with no statistical sig-
nificance in the PFS (P = 0.213; Log-Rank test) or OST (P = 0.3; Log-Rank test). 
When compared to other variables (Table 6), which affected the median 
PFS or OST, substage a had a significantly longer median PFS than substage b 
by both Log-Rank test (Fig. 3A) and Cox regression. The mL-CHOP also had a 
prolonged median PFS compared to the mL-COP by Log-Rank test (Fig. 3B). 
Clinical stage III had a significantly higher OST than the other stages by both 
Log-Rank test (Fig. 4) and Cox regression. 
 
 
Fig. 3. Kaplan-Meier analysis of (A) substage and (B) treatment effects on progression-free  
survival (PFS). Black circles indicate censored patients 
 
 
Discussion 
This study applied hPARR to monitor MRD during treatment for detecting 
refractory lymphoma. There was a good response to treatment in dogs with 
hPARR-negative and untraceable LNs, while hPARR positivity was associated 
with PR or PD. The rescue drugs or a secondary protocol, such as lomustine, 
doxorubicin or the second shot of L-asparaginase, were given in refractory cases. 
Three T-cell lymphomas were hPARR positive during the treatment even though 
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they had a CR. Therefore, in the case of neoplastic T-cell clones the molecular 
result and LN measurement should be interpreted concurrently. In our study, pe-
ripheral blood leukocytes at diagnosis showed clonal bands, which is dissimilar 
to the findings of previous studies (Lana et al., 2006; Aresu et al., 2014; Hiyoshi-
Kanemoto et al., 2016). However, we used different primer sets, which might af-
fect the sensitivity and specificity of the assay. In addition, this study classified 
clinical staging based on the blood smear technique instead of bone marrow bi-
opsy. We used the blood smear technique to detect lymphoblasts. If the sample 
had more than 50% of lymphoblasts, the dog was classified into clinical stage V. 
This indicates a stage migration from clinical stage III/IV to stage V due to 
hPARR positivity in all white blood cell samples (Flory et al., 2007). 
 
 
Fig. 4. Kaplan-Meier analysis represents the clinical stage that affected the prognosis of overall 
survival time (OST). Black circles indicate censored patients 
 
PARR analysis can be used for either diagnosis or MRD detection with 
suitable primers against the IgH and TCRγ genes (Tamura et al., 2006; Yagihara 
et al., 2007). A few difficulties were observed in the interpretation of results. One 
of them was the disagreement of immunophenotyping data and monoclonality 
from leucocyte samples in week 0. Even though the primer sets of the IgH genes 
designed by Tamura et al. (2006) showed 100% sensitivity and specificity in 
their study, the sample size was small. Our study found that this primer pair had 
a sensitivity of 57.1%. However, we detected genes from peripheral blood leuco-
cytes, while they used fine needle aspiration from LN. The TCRγ primer sets 
from Yagihara et al. (2007) represented a T-cell clonal assay in this study. Ac-
cording to their result, we only chose the primer sets of Vγa-Jγb and Vγb-Jγb. 
Our study reported a dissimilar sensitivity and specificity to theirs, but this may 
reflect experimental differences since they analysed clonal TCRγ gene rear-
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rangements from LNs and resolved the amplicons on 7.5% polyacrylamide gels. 
One study compared the visualising of PCR products by methods of TCRγ gene 
rearrangement. They found that agarose gel analysis had lower sensitivity than 
polyacrylamide gel and Genescan analysis (Costa et al., 2004). Different tumour 
cellularity between the peripheral blood leucocytes and LN samples could de-
crease the sensitivity of the primers. During the treatment, antineoplastic drugs 
killed the tumour cells, and so the enlarged LNs became smaller and contained 
necrotic tumour cells that were not suitable for the extraction of genomic DNA. 
Therefore, peripheral blood was more suitable for assessing MRD at the end of 
treatment by PARR (Aresu et al., 2014). Secondly, the product size of the mono-
clonal band of Vγb-Jγb should be in the 55–90 bp size range, but in our study it 
was observed at 200 bp. After DNA sequencing, the amplicons were found to 
have 100% nucleotide identity to canine TCRγ chain (FR828700.1), ruling out 
false and nonspecific amplicons. Moreover, another study reported that the prod-
uct size of Vγb or the V5-2 region was 140–190 bp (Keller et al., 2012). Lastly, 
some leucocyte samples during the remission phase (weeks 9 and 13) presented a 
monoclonal pattern of TCRγ genes. This could be due to the upregulation of 
normal T-cell population or to chemo-resistant T-cell lymphoma clones (Calzola-
ri et al., 2006).  
Even though PARR is a sensitive method for clonal recognition, pseudo-
clonality is an impediment due to the immunological diversity of IgH and TCRγ 
genes (Takanosu et al., 2010). Therefore, heteroduplex analysis was helpful to 
denature and renature polyclonal populations from the real monoclonal popula-
tion. In our study, pseudoclones after heteroduplex analysis appeared as faint 
bands as reported before (Takanosu et al., 2010). However, duplicate or triplicate 
bands can increase the reliability of the result if they are performed concurrently 
with the heteroduplex analysis, but it is more laborious and costly. Rather, capil-
lary electrophoresis and gene scanning have been shown to be more advanta-
geous in recent studies (Gentilini et al., 2009; Keller and Moore, 2012; Goto-
Koshino et al., 2015). 
Dogs with lymphoma showed a lower relapse rate after doxorubicin ad-
ministration than after vincristine and cyclophosphamide (Wang et al., 2016). 
Our study compared treatment efficacy between the mL-COP and mL-CHOP 
protocols using MRD detection with hPARR. However, due to the high varia-
tions and low sample sizes of B- and T-cell lymphoma groups for subsets, no 
meaningful differences could be demonstrated between the COP and the CHOP 
protocols by univariate and multivariate analysis. 
Fourteen dogs did not receive L-asparaginase for the first treatment in this 
study (8 mL, COP B-cell lymphoma, 5 mL, CHOP B-cell lymphoma, and 1 mL, 
COP T-cell lymphoma). In most cases (nine dogs), the owners rejected this drug 
because of its high cost, and in a few cases (five dogs) the dog had abnormal 
blood results at the time of first diagnosis, so vincristine without L-asparaginase 
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was applied as the first therapy. Four out of the 21 (19%) dogs treated with L-
asparaginase and vincristine showed neutropenia, which resulted in delayed 
treatment. There was no difference in median PFS and OST between treatments 
with and without L-asparaginase in both the COP and CHOP protocols, in ac-
cordance with previous studies (Northrup et al., 2002; MacDonald et al., 2005). 
One study observed the efficacy of L-asparaginase combined with CHOP and its 
toxicity. The minimal toxic effects were leukopenia and particularly neutropenia 
(neutrophils less than 1,500 cells/µl). L-asparaginase administered concurrently 
with vincristine might cause myelosuppression because L-asparaginase decreases 
the hepatic clearance of vincristine and increases its toxicity (Northrup et al., 
2002). Other adverse events were gastrointestinal signs. Moreover, there was no 
advantageous response to L-CHOP treatment over CHOP (MacDonald et al., 
2005). Also, comparison between COP and L-COP for the treatment of lympho-
ma in 76 dogs revealed that L-COP treatment did not increase the clinical remis-
sion or prolong the progression-free interval compared to COP treatment (Jef-
freys et al., 2005). According to our observation, both B- and T-cell lymphomas 
responded well to the first dose of L-asparaginase given concurrently with vin-
cristine, as LN size decreased by more than 75%. 
In conclusion, MRD detection from peripheral blood leucocytes by 
hPARR might be beneficial in the clinical practice for determining refractory 
lymphomas during the treatment. Because of the painless sampling method, it 
should be used concurrently with LN measurement as an indicator of treatment 
failure. In addition, the L-CHOP protocol tended to be a suitable treatment of 
both multicentric B- and T-cell lymphomas as it could prolong PFS and OST in 
dogs. 
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